Hypersomnia Therapeutics Market is segmented By Product (Antidepressants, Sodium Oxybate, Stimulants, Others), By Application (Idiopathic Hypersomnia,....
Market Size in USD
CAGR8.7%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 8.7% |
Market Concentration | Medium |
Major Players | Axsome Therapeutics, Avadel Pharmaceuticals, Zevra Therapeutics, Alkermes, Aucta Pharmaceuticals |
The Global Hypersomnia Therapeutics Market is estimated to be valued at USD 321.3 Mn in 2024 and is expected to reach USD 500.3 Mn by 2031, growing at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2031. The increasing prevalence of hypersomnia disorders such as narcolepsy, idiopathic hypersomnia and Kleine-Levin syndrome is an important factor driving the demand for Hypersomnia Therapeutics.
The market is witnessing favorable growth owing to rising awareness about diagnosis and treatment of hypersomnia disorders. Moreover, growing research and development activities for development of novel and targeted drugs for effective treatment of hypersomnia is expected to present lucrative opportunities for players in this market. Several pharmaceutical companies are conducting clinical trials for development of new drug candidates such as sodium oxybate, pitolisant and others which are expected to receive regulatory approvals in the coming years, further fueling the revenue growth of this market. However, difficulties associated with the diagnosis of hypersomnia disorders due to lack of biomarkers and conditions being underreported may hamper the market growth.